You are here

cancer

Is Biopharma Investing Too Much In Cancer R&D?

Is Biopharma Investing Too Much In Cancer R&D?

Forbes

Flag link:

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

Endpoints

Flag link:

We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated

We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated

San Francisco Gate, CA

Bristol-Myers Squibb

non-small cell lung cancer

Flag link:

Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors

Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors

CP Wire

Nektar Therapeutics

Flag link:

Novartis offloads failed cancer drug to Oncology Venture

Novartis offloads failed cancer drug to Oncology Venture

Fierce Biotech

Oncology Venture

Flag link:

Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study

Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study

Fierce Pharma

physician payments

Bristol-Myers Squibb

Flag link:

Visiongate Announces Next Step in Commercialization of Cancer Detection Platform

Visiongate Announces Next Step in Commercialization of Cancer Detection Platform

CP Wire

LuCED Lung Test

Flag link:

J&J loses trial over claims linking cancer to asbestos in talc

J&J loses trial over claims linking cancer to asbestos in talc

Yahoo/Reuters

Flag link:

In salvage effort, Sellas cherry picks some positive mid-stage cancer vaccine data

In salvage effort, Sellas cherry picks some positive mid-stage cancer vaccine data

Endpoints

Galena Biopharma

cancer vaccines

Flag link:

Compugen, AstraZeneca unit in cancer drug development deal

Compugen, AstraZeneca unit in cancer drug development deal

Yahoo/Reuters

drug development

Flag link:

Two Harvard Biotech Entrepreneurs Are Creating The "Trojan Horse" Of Cancer Treatment

Two Harvard Biotech Entrepreneurs Are Creating The "Trojan Horse" Of Cancer Treatment

Forbes

Flag link:

China's Aim to Remove Cancer Drug Taxes May Boost Pfizer, Glaxo

China's Aim to Remove Cancer Drug Taxes May Boost Pfizer, Glaxo

Bloomberg

Flag link:

Cotinga Pharmaceuticals Provides Update on COTI-2 PhI Clinical Programs

Cotinga Pharmaceuticals Provides Update on COTI-2 PhI Clinical Programs

CP Wire

Cotinga Pharmaceuticals

clinical trials

Flag link:

How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment

How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment

Motley Fool

prostate cancer

Merkel cell carcinoma

metastatic non-small cell lung cancer

metastatic breast cancer

Flag link:

MasSpec Pen Wins Award In Health, Med, Biotech Category at SXSW

MasSpec Pen Wins Award In Health, Med, Biotech Category at SXSW

CP Wire

Flag link:

FDA approves new dosing for Bristol-Myers Squibb's Opdivo

FDA approves new dosing for Bristol-Myers Squibb's Opdivo

Yahoo/Reuters

Bristol-Myers Squibb

Flag link:

[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important

[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important

Motley Fool

Sangamo Therapeutics

Flag link:

Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups

Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups

Xconomy

Flag link:

Merck to buy virus-based cancer drug firm Viralytics for $394 million

Merck to buy virus-based cancer drug firm Viralytics for $394 million

Reuters

Flag link:

Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug

Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug

Forbes

Bristol-Myers Squibb

Nektar Therapeutics

Flag link:

Pages